A Phase II Single Arm Study of High-Dose IL-2 and Ipilimumab in Patients With Unresectable Stage III and Stage IV Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Aldesleukin (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 25 Sep 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2021.
- 25 Sep 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2021.
- 31 Aug 2018 Biomarkers information updated